CHEMOTHERAPY FOR HORMONE REFRACTORY PROSTATE CANCER
- 1 May 1999
- journal article
- review article
- Published by Elsevier in Urologic Clinics of North America
- Vol. 26 (2) , 323-331
- https://doi.org/10.1016/s0094-0143(05)70072-0
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Phase II Study of Estramustine and Vinorelbine in Hormone-Refractory Prostate Carcinoma PatientsActa Oncologica, 1998
- Oral estramustine and oral etoposide for hormone-refractory prostate cancerUrology, 1997
- Phase II Study of Estramustine, Oral Etoposide, and Vinorelbine in Hormone-Refractory Prostate CancerAmerican Journal of Clinical Oncology, 1997
- Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostateUrologic Oncology: Seminars and Original Investigations, 1995
- Doxorubicin, Mitomycin C and 5-Fluorouracil in the Treatment of Hormone Refractory Adenocarcinoma of the Prostate: A Southwest Oncology Group StudyJournal of Urology, 1993
- Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I TrialJNCI Journal of the National Cancer Institute, 1993
- Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1992
- Mechanisms of Action and Clinical Uses of EstramustineCancer Investigation, 1990
- Nuclear protein matrix as a target for estramustine‐induced cell deathThe Prostate, 1986
- A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.Journal of Clinical Oncology, 1985